Drug Trial Radar · NCT01656538
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Feb 20, 2013
Primary completion
Nov 18, 2016
Study completion Feb 14, 2018
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- Oncolytics Biotech
- First posted
- Aug 3, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers doing this study want to evaluate the side effects of Reolysin when given together with paclitaxel. As these drugs have not been given together before, 6-9 patients will be treated with paclitaxel plus reolysin to ensure that side effects are tolerable.
Conditions
- Metastatic Breast Cancer
Interventions
PaclitaxelDrug
ReolysinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: 24 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
BCCA - Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
BCCA - Vancouver Island Cancer Centre
Victoria, British Columbia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Cancer Centre of Southeastern Ontario at Kingston
Kingston, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.